{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:29:16Z","timestamp":1787056156872,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inclisiran lowers LDL-cholesterol (LDL-C) by inhibiting hepatic PCSK9 synthesis. Whether concomitant statin therapy modifies the magnitude of inclisiran-associated LDL-C reduction in routine clinical practice remains uncertain. In this retrospective single-center observational study, 67 patients treated with inclisiran for at least 9 months were analyzed. Patients previously treated with PCSK9 monoclonal antibodies were excluded. LDL-C values were assessed longitudinally and stratified by concomitant statin therapy. Multivariable linear mixed-effects models were used to evaluate inclisiran-associated percentage LDL-C reduction over time. Thirty-seven patients received concomitant statin therapy and 30 patients did not. Median follow-up was 18 months (IQR 12.5\u201328). Median LDL-C reduction ranged from approximately\u2009\u2212\u200925% to \u2212\u200940% across follow-up visits. At 9 months, 10 of 59 patients (16.9%) achieved a\u2009\u2265\u200950% LDL-C reduction. In the primary multivariable longitudinal mixed-effects model, concomitant statin use was not significantly associated with percentage LDL-C reduction (\u03b2 for no statin vs. statin: 33.1% points; 95% CI\u2009\u2212\u20094.6 to 70.7;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.085). Statin intensity was also not significantly associated with LDL-C reduction (\u03b2\u2009\u2212\u20090.11 per percentage point of maximum approved dose; 95% CI\u2009\u2212\u20090.60 to 0.37;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.644). In an exploratory responder analysis, concomitant statin therapy was associated with higher odds of achieving\u2009\u2265\u200950% LDL-C reduction at 9 months (OR 7.69; 95% CI 1.28\u201345.45;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.026). During follow-up, 18 patients (26.9%) discontinued inclisiran, predominantly due to insufficient LDL-C reduction. In routine clinical practice, neither concomitant statin use nor statin intensity was significantly associated with the magnitude of LDL-C reduction observed during inclisiran therapy. However, responder and attrition sensitivity analyses suggested a possible association between concomitant statin therapy and a more pronounced inclisiran-associated LDL-C response. These findings support the clinical use of inclisiran in heterogeneous real-world populations, while highlighting the potential benefit of maintaining concomitant statin therapy whenever tolerated.\n                  <\/jats:p>","DOI":"10.1186\/s12872-026-06429-w","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:43:21Z","timestamp":1786754601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Maximilian","family":"Seidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Anft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Stervbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Babel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm H.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"6429_CR1","doi-asserted-by":"crossref","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events. New England. J Med. 2015;372(16):1489\u201399.","DOI":"10.1056\/NEJMoa1501031"},{"key":"6429_CR2","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and Safety of evolocumab in reducing lipids and cardiovascular events. New England. J Med. 2015;372(16):1500\u20139.","DOI":"10.1056\/NEJMoa1500858"},{"key":"6429_CR3","doi-asserted-by":"crossref","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. New England J Med. 2020;382(16):1507\u201319.","DOI":"10.1056\/NEJMoa1912387"},{"key":"6429_CR4","doi-asserted-by":"crossref","unstructured":"Landmesser U, Koenig W, Leiter LA, Raal FJ, Ray KK, Schwartz GG, Han J, Conde LG, Wright RS. Efficacy and safety of inclisiran based on background lipid-lowering treatment. Eur J Prev Cardiol. 2025.","DOI":"10.1093\/eurjpc\/zwaf214"},{"issue":"11","key":"6429_CR5","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","volume":"112","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Schatz U, Perakakis N, Kassner U, Schumann F, Axthelm C, Sturzebecher P, Sinning DL, Doevelaar A, Rohn B, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023;112(11):1639\u201349.","journal-title":"Clin Res Cardiol"},{"key":"6429_CR6","doi-asserted-by":"crossref","unstructured":"Alaiz AR, Gudino LC, de la Isla LP, Pardo HG, Calle DG, Miramontes-Gonzalez JP. Inclisiran: efficacy in real world-systematic review and meta-analysis. J Clin Med. 2025;14(12):4163.","DOI":"10.3390\/jcm14124163"},{"issue":"5","key":"6429_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jacc.2024.10.106","volume":"85","author":"P Gargiulo","year":"2025","unstructured":"Gargiulo P, Marzano F, Crisci M, Marcucci R, Bruzzese D, Maloberti A, Sarullo FM, Galasso G, Indolfi C, Musumeci G, et al. Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry). J Am Coll Cardiol. 2025;85(5):536\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"6429_CR8","doi-asserted-by":"crossref","unstructured":"Colivicchi F, Temporelli PL, Fattirolli F, Abrignani MG, Alonzo A, Arca M, et al. Sustainable and effective lipid-lowering management: prevention strategies from the BRING-UP prevention study. Eur Heart J Qual Care Clin Outcomes. 2026;12(4):632\u201343.","DOI":"10.1093\/ehjqcco\/qcag021"},{"issue":"1","key":"6429_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacl.2025.11.010","volume":"20","author":"A Faggiano","year":"2026","unstructured":"Faggiano A, Maloberti A, Ambrosetti M, Giallauria F, Mureddu G, Venturini E, Ruzzolini M, Maranta F, Vatri M, Zadre L, et al. From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: A Monte Carlo simulation within the ITACARE-P registry. J Clin Lipidol. 2026;20(1):21\u201330.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"6429_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","volume":"86","author":"PR Taub","year":"2025","unstructured":"Taub PR, Gutierrez A, Wewers D, Garcia Cantu E, Cao H, Deck C, Lesogor A, Ott D, Mena-Madrazo J, Zang X, et al. Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. J Am Coll Cardiol. 2025;86(3):196\u2013208.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"6429_CR11","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24(8):1454\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"6429_CR12","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1194\/jlr.M008144","volume":"51","author":"G Welder","year":"2010","unstructured":"Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010;51(9):2714\u201321.","journal-title":"J Lipid Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06429-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:49:41Z","timestamp":1787053781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6429"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06429-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee\/institutional review board of the Ruhr-University Bochum (approval number: 15-5279). Written informed consent was obtained from all participants prior to inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided informed consent to the pseudonymized processing of their data and to the publication of the resulting data in anonymized form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MS, FSS, and THW have received honoraria from Novartis for lectures. In addition, Novartis provided institutional research funding for a previous study conducted by their research group (\u201cBeyond lipid lowering: Effects of PCSK9 inhibition on inflammation and HDL function\u201d). The present study received no funding from Novartis. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"722"}}